PMID- 26576944 OWN - NLM STAT- MEDLINE DCOM- 20160812 LR - 20190108 IS - 1471-2342 (Electronic) IS - 1471-2342 (Linking) VI - 15 DP - 2015 Nov 17 TI - Prospective, randomized comparison of gadopentetate and gadobutrol to assess chronic myocardial infarction applying cardiovascular magnetic resonance. PG - 55 LID - 10.1186/s12880-015-0099-3 [doi] LID - 55 AB - BACKGROUND: We hypothesized that the contrast medium gadobutrol is not inferior compared to Gd-DTPA in identifying and quantifying ischemic late gadolinium enhancement (LGE), even by using a lower dose. METHODS: We prospectively enrolled 30 patients with chronic myocardial infarction as visualized by LGE during clinical routine scan at 1.5 T with 0.20 mmol/kg Gd-DTPA. Participants were randomized to either 0.15 mmol/kg gadobutrol (group A) or 0.10 mmol/kg gadobutrol (group B). CMR protocol was identical in both exams. LGE was quantified using a semiautomatic approach. Signal intensities of scar, remote myocardium, blood and air were measured. Signal to noise (SNR) and contrast to noise ratios (CNR) were calculated. RESULTS: Signal intensities were not different between Gd-DTPA and gadobutrol in group A, whereas significant differences were detected in group B. SNR of injured myocardium (53.5+/-21.4 vs. 30.1+/-10.4, p = 0.0001) and CNR between injured and remote myocardium (50.3+/-20.3 vs. 27.3+/-9.3, p < 0.0001) were lower in gadobutrol. Infarct size was lower in both gadobutrol groups compared to Gd-DTPA (group A: 16.8+/-10.2 g vs. 12.8+/-6.8 g, p = 0.03; group B: 18.6+/-12.0 g vs. 14.0+/-9.9 g, p = 0.0016). CONCLUSIONS: Taking application of 0.2 mmol/kg Gd-DTPA as the reference, the delineation of infarct scar was similar with 0.15 mmol/kg gadobutrol, whereas the use 0.10 mmol/kg gadobutrol led to reduced tissue contrast. TRIAL REGISTRATION: The study had been registered under EudraCT Number: 2010-020775-22. Registration date: 2010.08.10. FAU - Rudolph, Andre AU - Rudolph A AD - Working Group CMR, Experimental and Clinical Research Center, a joint cooperation between the Charite Medical Faculty and the Max-Delbruck Center for Molecular Medicine, Lindenberger Weg 80, 13125, Berlin, Germany. a.rudolph@charite.de. AD - Dept. of Cardiology and Nephrology, HELIOS-Kliniken Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. a.rudolph@charite.de. FAU - Messroghli, Daniel AU - Messroghli D AD - Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany. daniel.messroghli@charite.de. FAU - von Knobelsdorff-Brenkenhoff, Florian AU - von Knobelsdorff-Brenkenhoff F AD - Working Group CMR, Experimental and Clinical Research Center, a joint cooperation between the Charite Medical Faculty and the Max-Delbruck Center for Molecular Medicine, Lindenberger Weg 80, 13125, Berlin, Germany. Florian.Von-Knobelsdorff@charite.de. AD - Dept. of Cardiology and Nephrology, HELIOS-Kliniken Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. Florian.Von-Knobelsdorff@charite.de. FAU - Traber, Julius AU - Traber J AD - Working Group CMR, Experimental and Clinical Research Center, a joint cooperation between the Charite Medical Faculty and the Max-Delbruck Center for Molecular Medicine, Lindenberger Weg 80, 13125, Berlin, Germany. julius.traber@charite.de. AD - Dept. of Cardiology and Nephrology, HELIOS-Kliniken Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. julius.traber@charite.de. FAU - Schuler, Johannes AU - Schuler J AD - Working Group CMR, Experimental and Clinical Research Center, a joint cooperation between the Charite Medical Faculty and the Max-Delbruck Center for Molecular Medicine, Lindenberger Weg 80, 13125, Berlin, Germany. johannes.schueler@charite.de. AD - Dept. of Cardiology and Nephrology, HELIOS-Kliniken Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. johannes.schueler@charite.de. FAU - Wassmuth, Ralf AU - Wassmuth R AD - Working Group CMR, Experimental and Clinical Research Center, a joint cooperation between the Charite Medical Faculty and the Max-Delbruck Center for Molecular Medicine, Lindenberger Weg 80, 13125, Berlin, Germany. ralf.wassmuth@charite.de. AD - Dept. of Cardiology and Nephrology, HELIOS-Kliniken Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. ralf.wassmuth@charite.de. FAU - Schulz-Menger, Jeanette AU - Schulz-Menger J AD - Working Group CMR, Experimental and Clinical Research Center, a joint cooperation between the Charite Medical Faculty and the Max-Delbruck Center for Molecular Medicine, Lindenberger Weg 80, 13125, Berlin, Germany. jeanette.schulz-menger@charite.de. AD - Dept. of Cardiology and Nephrology, HELIOS-Kliniken Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. jeanette.schulz-menger@charite.de. LA - eng SI - EudraCT/2010-020775-22 PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20151117 PL - England TA - BMC Med Imaging JT - BMC medical imaging JID - 100968553 RN - 0 (Contrast Media) RN - 0 (Organometallic Compounds) RN - 1BJ477IO2L (gadobutrol) RN - K2I13DR72L (Gadolinium DTPA) SB - IM MH - Aged MH - Chronic Disease MH - Contrast Media MH - Female MH - Gadolinium DTPA MH - Humans MH - Image Interpretation, Computer-Assisted MH - Magnetic Resonance Imaging/*methods MH - Male MH - Middle Aged MH - Myocardial Infarction/*pathology MH - Organometallic Compounds MH - Prospective Studies PMC - PMC4650341 EDAT- 2015/11/19 06:00 MHDA- 2016/08/16 06:00 PMCR- 2015/11/17 CRDT- 2015/11/19 06:00 PHST- 2015/05/26 00:00 [received] PHST- 2015/11/09 00:00 [accepted] PHST- 2015/11/19 06:00 [entrez] PHST- 2015/11/19 06:00 [pubmed] PHST- 2016/08/16 06:00 [medline] PHST- 2015/11/17 00:00 [pmc-release] AID - 10.1186/s12880-015-0099-3 [pii] AID - 99 [pii] AID - 10.1186/s12880-015-0099-3 [doi] PST - epublish SO - BMC Med Imaging. 2015 Nov 17;15:55. doi: 10.1186/s12880-015-0099-3.